Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.55 USD | -0.63% |
|
+8.77% | -0.28% |
Jun. 18 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
Jun. 11 | Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.28% | 2.61B | C- | ||
+22.15% | 46.56B | B- | ||
+45.32% | 41.67B | A | ||
-2.37% | 41.16B | B | ||
+33.84% | 32.4B | B | ||
-6.35% | 28.1B | C | ||
+20.42% | 28.18B | B- | ||
+48.83% | 14.52B | B+ | ||
+45.00% | 13.74B | C+ | ||
+0.06% | 12.17B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLDX Stock
- Ratings Celldex Therapeutics, Inc.